relapsed/refractory lymphomas

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

relapsed/refractory lymphomas

Apr 15, 2024, 16:12 | Insight

Michael Wang: Our Phase I TRANSCEND trial demonstrated that Liso-cel results in consistently high objective response rates

Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and…

Apr 15, 2024, 04:04 | Blog

Amalya Sargsyan: Proud to see IMMONC spotlighted in ASCO's latest policy statement on global equity in clinical trials

Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, posted on LinkedIn: "Extremely proud to…

All: 2 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023